Oncoinvent ASA - Receipt of subscription rights in the rights issue by primary insiders and their close associates

14 November 2025: Reference is made to the stock exchange announcements published by Oncoinvent ASA (the "Company") on 30 June 2025 and 4 August 2025, and subsequent announcements, regarding the contemplated fully underwritten rights issue in the Company raising gross proceeds of NOK 130 million (the "Rights Issue"). In connection with the Rights Issue, tradable subscription rights have been allocated to, inter alia, certain of the Company's primary insiders and their close associates. Please see the attached notifications of trade for further information regarding the primary insiders' and their close associates' receipt of tradable subscription rights in the Rights Issue. For further information, please contact: Oystein Soug, Chief Executive Officer Email:(soug@oncoinvent.com) This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and Section 5-12 of the Norwegian Securities Trading Act. About Oncoinvent Oncoinvent is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The lead product candidate, Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting micro-metastases in the peritoneum post-surgery, harnessing the benefits of modern radiopharmaceuticals without the complexities of biological targeting. Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical development program in two indications. One Phase 1 trial and one Phase 1/2a trial have been completed and one randomized Phase 2 trial in ovarian cancer is currently ongoing in the US and Europe. Early clinical efficacy data are highly encouraging, and no serious toxicity or safety concerns have been reported to date. Oncoinvent runs a state-of-the-art manufacturing facility to produce drug products for clinical trials in Nydalen, Oslo. Oncoinvent is listed on the Oslo Stock Exchange. About Radspherin® Radspherin® is an innovative internal radiation therapy designed to directly target microscopic metastases in the abdominal cavity following surgery. Radspherin® is currently in development as a post-surgical treatment for patients with cancer that has spread to the abdominal cavity - a group with very limited treatment options today. The drug candidate offers a distinctly unique therapeutic approach with several differentiating features, including the use of radium-224, single-dose treatment with a sustained therapeutic effect, non -systemic administration, direct targeting and an exceptional dose-to-tumor ratio, maximizing efficacy while limiting harm to healthy tissue